RxDoctor Payments Data

Maria Baens, MD

Internal Medicine · Myrtle Beach, SCNPI 1447256672

Payments from drug & device makers

$1,497in general payments, 2019–2025

Across 72 payments — averaging $20.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$501
  • AstraZeneca$242
  • AbbVie$129
  • Exact Sciences$74
  • Abbott$69
  • Daiichi Sankyo Inc.$52
  • plus $430 from 15 others

What the payments were for

  • Food & beverage$1,497100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,497 in reported general payments places this provider in the 70th percentile of 1,498 internal medicine providers in South Carolina.

See all internal medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$170,890
Medicare patients
463
Services billed
1,898

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide110$158,691
MounjaroTirzepatide69$92,191
EliquisApixaban58$61,245
JardianceEmpagliflozin33$47,681
FarxigaDapagliflozin Propanediol40$44,173
JanuviaSitagliptin Phosphate22$34,578
TrulicityDulaglutide31$34,525
Repatha SureclickEvolocumab18$20,470
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$20,363
Tresiba Flextouch U-200Insulin Degludec15$14,342
Soliqua 100-33Insulin Glargine/Lixisenatide17$9,498
Breo ElliptaFluticasone/Vilanterol21$8,152
Levothyroxine Sodium399$5,705
Lantus SolostarInsulin Glargine,hum.Rec.Anlog43$5,584
Atorvastatin Calcium514$4,784

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$501$158,691110 claims
Lilly USA, LLCMounjaro, Trulicity$44$126,716100 claims
AstraZenecaFarxiga$242$44,17340 claims
GSKTrelegy Ellipta, Breo Ellipta$37$28,51539 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$18$9,49817 claims
AbbVieSynthroid$129$3,63555 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,498 internal medicine providers in South Carolina.

Other internal medicine in Myrtle Beach

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →